Fusion Antibodies – a “delighted to have secured” contract win, attempted ramptastic?

Fusion Antibodies (FAB) has issued a “Contract win” announcement with CEO Adrian Kinkaid emphasising “delighted to have secured this further project with an established pharmaceutical client… reflects… the value of Fusion’s specialist antibody development capabilities. The award also supports our strategy of developing deeper relationships with major pharmaceutical companies, providing opportunities for further collaboration and a more diversified revenue base”. What about that from a current 5.75p share price, £7.2 million market cap here?

Fusion Antibodies – argues “encouraging scientific and technological progress”, but there’s not financial progress. Hopefully my warning was heeded…

Most recently on company describing itself as “specialists in pre-clinical antibody discovery, engineering and supply” Fusion Antibodies (FAB), last month with the shares falling below 10p I concluded, with the financial position, an approx. £12 million market cap still sell. The shares most recently closed at 9.75p and what about now an “AGM statement H1 trading and research update” announcement?

Fusion Antibodies – full-year results argue “another year of important progress”, but why then not announced until now?…

‘Specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications’, Fusion Antibodies (FAB) has announced results for its year ended 31st March 2026 including “another year of important progress for the company. We had revenue growth, a significant improvement in gross margin and a stronger cash position… Scientifically, we have continued to make excellent progress”. However, why has it not announced the results until now? – and I note I previously wrote on the company in May; ‘Japan patent grant, “excellent news” or rather attempted ramptastic?’.

Fusion Antibodies – Japan patent grant, “excellent news” or rather attempted ramptastic?

Fusion Antibodies (FAB) has announced “grant of patent in Japan… excellent news… strengthens antibody discovery platform and licensing opportunities”. What about a current share price up to 14.5p?

Fusion Antibodies – trading statement argues “a solid foundation for future growth”. Er, really?…

Fusion Antibodies (FAB) has issued a “trading statement” headlined “Positioning for growth through platform development and strategic partnerships” and including that it “continues to benefit from a combination of commercial revenues and non-dilutive funding sources, including FMI and other grant programmes. The board remains focused on careful cash management while continuing to invest in high-value R&D programmes and commercial initiatives”. So what about a current share price response to 12.75p, approaching 9% lower?

Fusion Antibodies – “placing and subscription”, but I thought it had ‘adequate resources’?…

Recently writing on ‘antibody services’ company Fusion Antibodies (FAB) I’ve noted it having stated a reasonable expectation that it has adequate resources to continue in operational existence for at least a year but I suggesting financials and attempted ramptastic caution… and what of now a “Placing and Subscription to raise approx £1.4m” announcement?

Fusion Antibodies (#FAB) – “placing and subscription to raise approx £1.4m” at 13p per share

Fusion Antibodies – “Launch of OptiMAL platform” ‘delight’, how delightful is the financial position?…

Stating it “has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue”, ‘antibody engineering services’ contract research organisation Fusion Antibodies (FAB) has issued a “Launch of OptiMAL platform”-titled announcement which includes emphasising “look forward to the future of using this technology to bring more human therapeutic antibodies to the market”. What about currently an approaching 6% lower share price response to below 17p?

Fusion Antibodies – emphasises “delighted” with ‘R&D Update’, but what about the “cash runway”?…

Fusion Antibodies (FAB) has issued an ‘R&D Update’ announcement including that “having already demonstrated superior single digit nM affinities for antibodies against protein targets… now shown to be similarly successful with smaller peptide targets”. How material is this, with the shares currently approaching 4% higher at 14p in response?

Fusion Antibodies – argues “very pleased to deliver an improved FY2025”, but how ‘pleasing’ really is it?…

Despite its current half year ending at the end of this month, Fusion Antibodies (FAB) only now announces results for its year ended 31st March 2025. CEO Adrian Kinkaid states that the company is “very pleased to deliver an improved FY2025” but, with the shares currently responding 3% lower to 16.5p, how ‘pleasing’ actually is its “improved FY2025”?

Fusion Antibodies – a “delighted… Contract Win” or a “modest revenues… project under an existing Master Service Agreement”?!…

Fusion Antibodies (FAB) has issued a “Contract Win” announcement including CEO Adrian Kinkaid emphasising “delighted to have been selected to humanise a family of antibodies for our client. It is particularly gratifying that a client of this magnitude and with all the resources available to it has selected Fusion to undertake this critical work”. So how ‘delightful’ is this “contract win” relative to a current 15p share price, £17 million market cap?

Fusion Antibodies – trading update argues “securely positioned the company on a sound footing for growth”. But is it really?…

Most recently writing on Fusion Antibodies (FAB), in March I noted a placing announcement included that “trading for the full year ending 31 March 2025 is expected to be broadly in line with current market expectations, with revenue of not less than £1.9 million” but the bottom-line excluded and that it will be very interesting to see the full-year results detail and balance sheet. So what is included today in a “Trading update”?

Fusion Antibodies – argues a “delighted” by “enthusiasm” shown placing, but does it really provide vast growth potential or is it to be needed to ‘keep the lights on’?…

Most recently writing on company describing itself as “specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications” Fusion Antibodies (FAB), in December with the shares soaring to above 6p I concluded that I remained unconvinced of a sustainable funding platform and to still avoid. The shares went on to exceed 10p in January, most recently closed at 6.75p and now a placing announcement…

Fusion Antibodies (#FAB) – £1.17m placing at 6.75p per share

Fusion Antibodies – “Approval of Grant Funding Application”, shares soar but how justifiably so?…

Belfast-based antibody contract research company Fusion Antibodies (FAB) has issued an “Approval of Grant Funding Application”-titled announcement, and what of the shares currently up approaching 50% in response to above 6p?

Fusion Antibodies – interims argue “now well positioned”, but is it really?…

Antibody contract research company Fusion Antibodies (FAB) has announced results for its half-year ended 30th September 2024 with CEO Adrian Kinkaid emphasising that “the company is now well positioned, generating the financial evidence of a significant recovery and promising growth in the company's prospects”. What then of a current share price response more than 7.5% lower to 4.25p?

Fusion Antibodies – argues trading “positive momentum”, but how positive really?

Antibody contract research company Fusion Antibodies (FAB) has issued a “Trading update” highlighting “Positive momentum through the first quarter of the current financial year ending 31 March 2025… continuing confidence for growth in the remainder of FY2025”. So what of a share price slightly up to 3.15p, but comparing to rising above 6p as recently as January?

Fusion Antibodies – discounted placing as I warned, but a share options ‘up yours’ to external shareholders too!

Just last week with its shares rising above 5p on a “pleased to announce” follow-on project award, I cautioned on antibody contract research company Fusion Antibodies (FAB) to be particularly wary of the attempted ramptastic considering its funding situation and to avoid/sell. It hasn’t taken long for a “placing” announcement!

Fusion Antibodies (#FAB) – conditionally raised £1.375m at 4p per share

Fusion Antibodies – “follow-on project award”, but still how’s that ‘cash runway’?

Fusion Antibodies (FAB) is pleased to announce that it has received a follow-on project under a collaborative research and development agreement with a US-based biotechnology company. With the shares currently up nearly 8% at 5.125p in response, what’s the detail and impact for the company?